Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs). METHODS: Eligible patients received daily temozolomide (50 mg/m(2)) continuously until progression. The primary endpoint was progression-free...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Omuro, Antonio, Chan, Timothy A., Abrey, Lauren E., Khasraw, Mustafa, Reiner, Anne S., Kaley, Thomas J., DeAngelis, Lisa M., Lassman, Andrew B., Nolan, Craig P., Gavrilovic, Igor T., Hormigo, Adilia, Salvant, Cynthia, Heguy, Adriana, Kaufman, Andrew, Huse, Jason T., Panageas, Katherine S., Hottinger, Andreas F., Mellinghoff, Ingo
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548585/
https://ncbi.nlm.nih.gov/pubmed/23243055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos295
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados